Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...

So, you like games? Vulture’s Movies Fantasy League just kicked off its new season. It’s fun, it’s free, and there are some killer prizes on the line. Sign up to play here, or learn more at the MFL ...